Knights of Columbus Asset Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-130,032	Closed	-$1.04M	–	420
2026 Q1	$1.04M	Sell	130,032 -697	-0.5%	-$6.68K	0.06%	263
2025 Q4	$1.52M	Sell	130,729 -3,747	-3%	-$36.4K	0.09%	228
2025 Q3	$1.35M	Buy	134,476 +66,382	+97%	+$953K	0.08%	238
2025 Q2	$1.19M	Buy	68,094 +24,950	+58%	+$360K	0.07%	239
2025 Q1	$543K	Buy	+43,144	New	+$519K	0.04%	261

Other funds holding SPRY

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

NFGCM

Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Knights of Columbus Asset Advisors's SPRY Position: Q2 2026 in Review

Knights of Columbus Asset Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 130,032 shares — an estimated $1.04M sold.

Knights of Columbus Asset Advisors first reported a position in SPRY in Q1 2025 and held it in 5 quarters. The position peaked at $1.52M in Q4 2025. 35 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Knights of Columbus Asset Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 130,032 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.04M.
Knights of Columbus Asset Advisors first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 5 quarters.
Knights of Columbus Asset Advisors's ARS Pharmaceuticals position peaked at $1.52M in Q4 2025.
35 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.